Lanadelumab Market
The market for Lanadelumab was estimated at $628 million in 2024; it is anticipated to increase to $1.08 billion by 2030, with projections indicating growth to around $1.70 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Lanadelumab Market Outlook
Revenue, 2024
$628M
Forecast, 2034
$1.56B
CAGR, 2025 - 2034
9.5%
The Lanadelumab industry revenue is expected to be around $687.1 million in 2025 and expected to showcase growth with 9.5% CAGR between 2025 and 2034. The rise in Lanadelumabs popularity is a result of its effectiveness in treating hereditary angioedema (HAE) as well as the increasing global investment in healthcare services and awareness of HAE conditions among the publics around the world People are embracing Lanadelumab due to its ability to address these needs effectively and drive growth, in the HAE treatment field while maintaining its importance.
A drug called Lanadelumab, also known as Takhzyro, is very good at stopping HAE attacks. A dangerous condition. Because it focuses on blocking plasma kallikrein enzyme linked to HAEs symptoms in the body. The fact that it can be given under the skin makes it more convenient, for patients compared to treatments that need to be given into a vein.
Market Key Insights
The Lanadelumab market is projected to grow from $627.5 million in 2024 to $1.56 billion in 2034. This represents a CAGR of 9.5%, reflecting rising demand across Hereditary Angioedema Prophylaxis, High-Risk Patient Treatment, and Biopharmaceutical Research.
Takeda Pharmaceuticals is the sole producer in this market, holding full control over supply and pricing.
U.S. and Germany are the top markets within the Lanadelumab market and are expected to observe the growth CAGR of 6.9% to 10.0% between 2024 and 2030.
Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 9.1% to 11.9%.
Slow adoption of Tackling Hereditary Angioedema transition within key players in Lanadelumab market is creating a revenue window for adjacent and alternate markets like Orladeyo and C1 Inhibitor Replacement Therapies to improve its use-case penetration in HAE Type I and HAE Type II applications and expected to capture $55 million revenue from existing Lanadelumab market.
The Lanadelumab market is set to add $928 million between 2024 and 2034, with manufacturer targeting Homecare & Specialty Centers Application projected to gain a larger market share.
With
increasing incidence of hereditary angioedema, and
Breakthroughs in Therapeutic Technology, Lanadelumab market to expand 148% between 2024 and 2034.
Opportunities in the Lanadelumab
The pharmaceutical industry is also experiencing changes due to technological advancements. Innovative products like Lanadelumab have the opportunity to benefit from this by partnering with other major pharmaceutical companies. These collaborations could lead to improvements, in drug delivery methods efficiency and broader networking capabilities resultantly supporting the growth of Lanadelumab.
Growth Opportunities in North America and Europe
The market for Lanadelumab is experiencing growth in North America due to a rising need for effective treatments for hereditary angioedema. The region has healthcare facilities especially in the United States that are driving innovative research in new medications like Lanadelumab. The flourishing pharmaceutical sector in America plays a role in boosting the market for Lanadelumab along with substantial investments, in medical research and development efforts. North America's advanced adoption of Lanadelumab for treating angioedema is evident through the crowded market and fierce competition it faces in the regions mature market landscape. The factors driving this market include advancements in bioengineering technology increased spending, on healthcare and growing awareness of genetic conditions.
In Europe at the time there are encouraging opportunities for researching Lanadelumab due to a changing healthcare approach that emphasizes personalized medicine. Leading the way in the use of Lanadelumab are the United Kingdom, Germany and France supported by a pharmaceutical sector that enables the development of new treatments. Significantly the competitive situation for Lanadelumab, in Europe is influenced by market participants who are driving progress in treating hereditary angioedema. The main factors influencing this region are the increasing cases of angioedema and strong healthcare regulations and increased healthcare expenditures.
Market Dynamics and Supply Chain
01
Driver: Increasing hereditary angioedema diagnosis and growing preference for targeted biologic therapies
The lanadelumab market is also driven by the rising diagnosis rate of hereditary angioedema and the growing clinical preference for targeted biologic therapies. Improved genetic screening, wider clinical awareness, and expanded diagnostic protocols have also increased identification of HAE patients who require long-term management, enlarging the addressable patient population. Parallel to this, clinicians and patients are also increasingly adopting monoclonal antibody therapies like lanadelumab due to their specificity, sustained efficacy, and reduced attack rates compared with older treatments. also advances in biologic development have also improved safety profiles and extended dosing intervals, enhancing patient adherence and quality of life. These factors collectively encourage healthcare providers to shift toward precision biologics for prophylaxis, supporting robust market demand and reinforcing lanadelumab’s role as a first-line preventive option in specialized immunology and rare disease care.
A key trend driving the lanadelumab market is also the expansion of patient-centric delivery models, including home administration and user-friendly injection platforms. Lanadelumab’s subcutaneous formulation enables self-administration or caregiver administration outside clinical settings, reducing the burden of frequent hospital visits and improving convenience. This trend resonates with broader healthcare shifts toward decentralized care and chronic disease management at home. Easier delivery fosters better adherence to prophylactic regimens, translating to sustained therapeutic outcomes and reduced emergency interventions. The resulting improvement in patient experience and healthcare resource utilization supports broader uptake among HAE patients globally.
02
Restraint: High treatment costs and limited insurance reimbursement constrain lanadelumab adoption
A major restraint on the lanadelumab market is its high cost relative to alternative therapies, which limits access and uptake, especially in markets with restricted insurance coverage. As a biologic therapy for hereditary angioedema prophylaxis, lanadelumab can carry substantial per-dose pricing, and patients may face significant out-of-pocket expense when reimbursement is inadequate. For example, in certain emerging economies or private pay settings, budget-constrained healthcare providers may prioritize cheaper alternatives or delay adoption, reducing overall demand. This cost sensitivity can slow revenue growth for manufacturers and restrict long-term treatment consistency among diagnosed patients.
03
Opportunity: Expanding Genre of Antiallergic Medication and Embracing Global Market Expansion
Lanadelumab stands out among medications due to its monoclonal antibody nature in the ever changing medical field landscape. Hereditary angioedema is the target condition for Lanadelumab treatment and is an area that lacks sufficient research and treatment options. There is potential for growth, in addressing the needs of this underexplored segment through strategic partnerships focused on thorough research and development efforts.
The growing recognition and changing demands of consumers for healthcare options on a global scale present a promising opportunity for Lanadelumab to enter new markets successfully. Look into and addressing these requirements. Particularly, in less developed nations. has the potential to solidify Lanadelumabs presence worldwide and generate significant profits.
04
Challenge: Competition from alternative therapies and emerging treatment modalities reduces market share
Another key restraint is increasing competition from alternative therapies, including oral prophylactics like berotralstat and other biologics or C1-inhibitors that challenge lanadelumab’s market position. As clinicians adopt newer or more convenient options, prescribing patterns may shift away from lanadelumab, eroding its share in HAE management. For instance, broader use of C1-esterase inhibitors for both acute and prophylactic use can diminish lanadelumab’s exclusivity in certain patient subgroups. This competitive environment creates pricing pressure and necessitates continued investment in differentiation, potentially slowing revenue expansion and altering demand behavior.
Supply Chain Landscape
1
Biologic API Production
Lonza GroupWuXi Biologics
2
Drug Substance Processing
Takeda PharmaceuticalsLonza Group
3
Fill–Finish Manufacturing
Takeda Pharmaceuticals
4
Distribution & End Users
Pharmacy ChainsHospitalsSpecialty Clinics
1
Biologic API Production
Lonza GroupWuXi Biologics
2
Drug Substance Processing
Takeda PharmaceuticalsLonza Group
3
Fill–Finish Manufacturing
Takeda Pharmaceuticals
4
Distribution & End Users
Pharmacy ChainsHospitalsSpecialty Clinics
Use Cases of Lanadelumab in Hereditary Angioedema Prophylaxis & Biopharmaceutical Research
Hereditary Angioedema Prophylaxis : Lanadelumab is predominantly used as a long-term prophylactic therapy for patients with hereditary angioedema to prevent recurrent and unpredictable swelling attacks. Administered as a subcutaneous monoclonal antibody injection, it works by selectively inhibiting plasma kallikrein, thereby reducing bradykinin production that triggers edema. This targeted mechanism offers sustained attack prevention with dosing every two to four weeks, improving treatment adherence. Its high efficacy in reducing attack frequency makes lanadelumab a preferred option for patients requiring consistent, preventive management rather than on-demand therapy, supporting better quality of life and reduced emergency care dependence.
High-Risk Patient Treatment : In high-risk patient treatment, lanadelumab is mainly prescribed for individuals experiencing frequent, severe, or life-threatening hereditary angioedema attacks, including those with prior airway involvement. The injectable monoclonal antibody formulation provides stable kallikrein inhibition, offering reliable protection for patients with poor response or intolerance to older prophylactic options. Its predictable pharmacokinetic profile allows clinicians to tailor dosing intervals based on patient risk levels. This application is particularly valuable in specialized allergy and immunology clinics, where reducing hospitalization risk, work disruption, and psychological stress associated with severe HAE attacks is a key therapeutic objective.
Biopharmaceutical Research : Lanadelumab also plays an important role in biopharmaceutical research focused on rare diseases and targeted antibody therapies. In this application, it is primarily used as a reference monoclonal antibody to study plasma kallikrein inhibition and bradykinin pathway modulation. Researchers leverage lanadelumab to evaluate long-acting biologic design, dosing optimization, and real-world effectiveness in rare disease populations. Its success has encouraged further investment in monoclonal antibody platforms and precision therapies, influencing broader research efforts in inflammatory and complement-mediated disorders and advancing innovation across the rare disease biopharmaceutical landscape.
Recent Developments
there have been advances in the field of healthcare with Takhzyro being used as an innovative treatment for hereditary angioedema. This progress has greatly improved the effectiveness of Takhzyro therapy. Opened up new possibilities for its use, in various applications.
February 2025 : Takeda announced that the European Medicines Agency approved an additional 2 mL pre-filled pen option for subcutaneous administration of TAKHZYRO in adolescents (≥12 years) and adults with hereditary angioedema, expanding delivery options to support individualized treatment.
February 2023 : Takeda’s TAKHZYRO received U.S. Food and Drug Administration approval for prophylaxis to prevent HAE attacks in pediatric patients 2 years of age and older, marking the first prophylactic HAE treatment for children as young as 2 years in the U.S.
Impact of Industry Transitions on the Lanadelumab Market
As a core segment of the Pharmaceutical industry,
the Lanadelumab market develops in line with broader industry shifts.
Over recent years, transitions such as Tackling Hereditary Angioedema and Advent of Subcutaneous Administration have redefined priorities
across the Pharmaceutical sector,
influencing how the Lanadelumab market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Tackling Hereditary Angioedema
The introduction of Lanadelumab represents an advancement in the field of healthcare with a particular focus on treating Hereditary Angioedema . This specialized monoclonal antibody treatment has demonstrated promising outcomes by decreasing the frequency of HAE attacks and enhancing the well being of individuals affected by the condition. This innovation has led to a transition, from short term symptom management to term preventive therapies that prioritize averting attacks rather than solely addressing symptoms after they occur. The shift has motivated firms to allocate significant resources, towards research and development efforts to foster advancements in the sector.
02
Advent of Subcutaneous Administration
The advent of subcutaneous administration with lanadelumab marks a meaningful transition in the hereditary angioedema treatment landscape. By enabling self injection every two to four weeks, lanadelumab has reduced reliance on hospital based intravenous therapies, improving patient convenience and long term adherence. This shift has influenced home healthcare services, as demand has grown for patient training, specialty pharmacy support, and cold chain distribution tailored to self administered biologics. Pharmaceutical companies have also adjusted formulation and packaging strategies to support ease of use and safety in non clinical settings. In parallel, healthcare systems benefit from reduced infusion center burden and lower procedural costs, allowing resources to be redirected to acute care. Overall, this transition has reshaped treatment delivery models while supporting broader adoption of preventive HAE therapies.